TY - JOUR
T1 - Kidney transplantation improves survival and is indicated in Fabry's disease
AU - Inderbitzin, D.
AU - Avital, I.
AU - Largiadèr, F.
AU - Vogt, B.
AU - Candinas, D.
PY - 2005/12/1
Y1 - 2005/12/1
N2 - Background. Fabry's disease (FD) is an inborn error of glycosphingolipid catabolism with progressive systemic deposition of globotriaosylceramide thereby leading to renal and cardiac failure. Current therapy involves symptomatic medical management, dialysis, enzyme replacement therapy, kidney transplantation (KTx), and more recently gene therapy. Case fatalities occur in the fourth decade of life resulting from uremia unless dialysis or KTx is undertaken. Study Design. This is a retrospective study aimed at determining the effect of KTx on the long-term outcome of patients with FD. Results. Between 1964 and 1998, ten patients with FD received KTx at our institutions. Actuarial patient and graft survivals were 100% and 90% at 5 years; 76% and 66% at 10 years. One kidney graft was lost due to rejection. Patient survival data compared favorably at 5 years with survival of FD patients on hemodialysis alone (41%, P < .05). Five patients are alive at the time of this study, and five patients died with median survival time after KTx of 128 months (range: 74-160 months). Conclusions. This study demonstrates an excellent outcome in patients with FD in the first decade after KTx. In the absence of a severe contraindication, we advocate KTx to improve the overall prognosis of patients with renal failure due to FD. Based on the data, enzyme replacement therapy after KTx seems indicated, as FD progresses posttransplant, leading to case fatalities in the second decade after KTx.
AB - Background. Fabry's disease (FD) is an inborn error of glycosphingolipid catabolism with progressive systemic deposition of globotriaosylceramide thereby leading to renal and cardiac failure. Current therapy involves symptomatic medical management, dialysis, enzyme replacement therapy, kidney transplantation (KTx), and more recently gene therapy. Case fatalities occur in the fourth decade of life resulting from uremia unless dialysis or KTx is undertaken. Study Design. This is a retrospective study aimed at determining the effect of KTx on the long-term outcome of patients with FD. Results. Between 1964 and 1998, ten patients with FD received KTx at our institutions. Actuarial patient and graft survivals were 100% and 90% at 5 years; 76% and 66% at 10 years. One kidney graft was lost due to rejection. Patient survival data compared favorably at 5 years with survival of FD patients on hemodialysis alone (41%, P < .05). Five patients are alive at the time of this study, and five patients died with median survival time after KTx of 128 months (range: 74-160 months). Conclusions. This study demonstrates an excellent outcome in patients with FD in the first decade after KTx. In the absence of a severe contraindication, we advocate KTx to improve the overall prognosis of patients with renal failure due to FD. Based on the data, enzyme replacement therapy after KTx seems indicated, as FD progresses posttransplant, leading to case fatalities in the second decade after KTx.
UR - http://www.scopus.com/inward/record.url?scp=29544435188&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2005.11.021
DO - 10.1016/j.transproceed.2005.11.021
M3 - Article
C2 - 16387080
AN - SCOPUS:29544435188
SN - 0041-1345
VL - 37
SP - 4211
EP - 4214
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 10
ER -